Sunshine Biopharma (SBFM) Gross Profit (2018 - 2026)

Sunshine Biopharma's Gross Profit history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Gross Profit fell 20.12% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 5.98% YoY) and the FY2025 annual result came in at $12.3 million, up 14.86% from the prior year.
• Gross Profit was $2.2 million for Q1 2026 at Sunshine Biopharma, down from $3.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $3.4 million in Q2 2025 and bottomed at $62800.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $2.4 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 6157.61% — and 2026, when it declined 20.12%.
• Sunshine Biopharma's Gross Profit stood at $1.5 million in 2022, then soared by 72.22% to $2.6 million in 2023, then gained by 20.44% to $3.1 million in 2024, then dropped by 2.08% to $3.0 million in 2025, then decreased by 27.99% to $2.2 million in 2026.
• Business Quant data shows SBFM's Gross Profit at $2.2 million in Q1 2026, $3.0 million in Q4 2025, and $3.1 million in Q3 2025.